Cargando…

Clinical and immunological effects of mRNA vaccines in malignant diseases

In vitro-transcribed messenger RNA-based therapeutics represent a relatively novel and highly efficient class of drugs. Several recently published studies emphasize the potential efficacy of mRNA vaccines in treating different types of malignant and infectious diseases where conventional vaccine str...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heine, Annkristin, Juranek, Stefan, Brossart, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957288/ https://www.ncbi.nlm.nih.gov/pubmed/33722265 http://dx.doi.org/10.1186/s12943-021-01339-1

Ejemplares similares

Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning
por: Wolf, Dominik, et al.
Publicado: (2014)

G-quadruplexes: a promising target for cancer therapy
por: Kosiol, Nils, et al.
Publicado: (2021)

RNA Vaccines in Cancer Treatment
por: Bringmann, Anita, et al.
Publicado: (2010)

Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy
por: Rittig, Susanne M., et al.
Publicado: (2015)

Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors
por: Mispelbaum, Rebekka, et al.
Publicado: (2022)

Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah’s Witness patient
por: Schlaweck, Sebastian, et al.
Publicado: (2021)

Two cases of EBV infection preceding lymphoma
por: Saal, Jonas, et al.
Publicado: (2022)

The Relevance of G-Quadruplexes for DNA Repair
por: Linke, Rebecca, et al.
Publicado: (2021)

Dexamethasone induced inhibition of Dectin-1 activation of antigen presenting cells is mediated via STAT-3 and NF-κB signaling pathways
por: Kotthoff, Philipp, et al.
Publicado: (2017)

Elotuzumab spares dendritic cell integrity and functionality
por: Schlaweck, Sebastian, et al.
Publicado: (2021)

SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond
por: Bettini, Emily, et al.
Publicado: (2021)

BG-flow, a new flow cytometry tool for G-quadruplex quantification in fixed cells
por: De Magis, Alessio, et al.
Publicado: (2021)

The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
por: Braun, Christiane, et al.
Publicado: (2021)

mRNA vaccines: the most recent clinical applications of synthetic mRNA
por: Kwon, Suji, et al.
Publicado: (2022)

Baseline immune signature score of Tregs × HLA-DR(+)CD4(+) T cells × PD1(+)CD8(+) T cells predicts outcome to immunotherapy in cancer patients
por: Mispelbaum, Rebekka, et al.
Publicado: (2022)

Spoilt for choice: different immunosuppressive potential of anaplastic lymphoma kinase inhibitors for non small cell lung cancer
por: Heine, Annkristin, et al.
Publicado: (2023)

mRNA as a Therapeutics: Understanding mRNA Vaccines
por: Oğuz, Ferdi, et al.
Publicado: (2022)

mRNA Vaccine Platform: mRNA Production and Delivery
por: Litvinova, V. R., et al.
Publicado: (2023)

SARS-CoV-2 PrEP complicates antibody testing after vaccination: a call for awareness
por: Monin, Malte B., et al.
Publicado: (2022)

mRNA vaccines in the prevention and treatment of diseases
por: Gu, Yangzhuo, et al.
Publicado: (2022)

mRNA-Based Vaccines
por: Kowalzik, Frank, et al.
Publicado: (2021)

Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects
por: Kiaie, Seyed Hossein, et al.
Publicado: (2022)

mRNA vaccines in disease prevention and treatment
por: Zhang, Gang, et al.
Publicado: (2023)

Immunological Analysis of a CCHFV mRNA Vaccine Candidate in Mouse Models
por: Aligholipour Farzani, Touraj, et al.
Publicado: (2019)

Identification of Potential Antigens for Developing mRNA Vaccine for Immunologically Cold Mesothelioma
por: Zhang, Shichao, et al.
Publicado: (2022)

mRNA vaccines for infectious diseases: principles, delivery and clinical translation
por: Chaudhary, Namit, et al.
Publicado: (2021)

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
por: Schwab, Katjana S., et al.
Publicado: (2018)

RNA modification in mRNA cancer vaccines
por: Mei, Yingxue, et al.
Publicado: (2023)

Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines
por: Guo, Xiao, et al.
Publicado: (2023)

Neo-Antigen mRNA Vaccines
por: Esprit, Arthur, et al.
Publicado: (2020)

COVID-19 mRNA vaccines
por: Huang, Qingrui, et al.
Publicado: (2021)

mRNA Vaccines against Flaviviruses
por: Wollner, Clayton J., et al.
Publicado: (2021)

mRNA vaccine for cancer immunotherapy
por: Miao, Lei, et al.
Publicado: (2021)

The Delivery of mRNA Vaccines for Therapeutics
por: Nitika,, et al.
Publicado: (2022)

Determination of significant immunological timescales from mRNA-LNP-based vaccines in humans
por: Moyles, Iain R., et al.
Publicado: (2023)

mRNA vaccines for COVID-19 and diverse diseases
por: Hussain, Abid, et al.
Publicado: (2022)

Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies
por: Crombie, Jennifer L., et al.
Publicado: (2021)

Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies
por: Vermeij, R., et al.
Publicado: (2011)

Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency
por: Kim, Sun Chang, et al.
Publicado: (2021)

Decoding the Human Genetic and Immunological Basis of COVID-19 mRNA Vaccine-Induced Myocarditis
por: Bolze, Alexandre, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qhsvkd4gpik6if8cfcd852k7nq